ABSTRACT
Globally, child mortality rates have been halved over the last few decades, a developmental success story. Nevertheless, progress has been uneven and in recent years mortality rates have increased in some countries. The present study documents the slowing decline in infant mortality rates in india; a departure from the longer-term trends. The major causes of childhood mortality are also reviewed and strategic options for the different states of India are proposed that take into account current mortality rates and the level of progress in individual states. The slowing decline in childhood mortality rates in India calls for new approaches that go beyond disease-, programme- and sector-specific approaches.
Subject(s)
Infant Mortality/trends , Adult , Child Health Services , Child Nutritional Physiological Phenomena , Child, Preschool , Female , Humans , Income , India/epidemiology , Infant , Infant, Newborn , Male , Maternal Welfare , Middle Aged , Mothers/classification , Mothers/statistics & numerical data , Sex Factors , Socioeconomic FactorsABSTRACT
A slow, continuous infusion of 1000 mug TRH (thyrotropin releasing hormone) over a period of 4 h had a very faint and diffuse short-lasting beneficial effect on a group of 10 depressive patients. This was assessed in a double blind cross-over trial with placebo. The effect was of no therapeutic value. No difference was found between the depressive patients and a control group of normal subjects in TSH response, T3 resin uptake, T4 or free thyroxine index values as a consequence of the TRH infusion.
Subject(s)
Depression/drug therapy , Thyrotropin-Releasing Hormone/administration & dosage , Adjustment Disorders/drug therapy , Adult , Bipolar Disorder/drug therapy , Chronic Disease , Clinical Trials as Topic , Dose-Response Relationship, Drug , Female , Humans , Infusions, Parenteral , Male , Mental Status Schedule , Middle Aged , Thyrotropin/bloodABSTRACT
In a double reversal design the potency of thyrotropin releasing hormone (TRH) (500 mug intravenously) as a quick-acting antidepressive agent was evaluated. A first injection did seem to give rise to a very slight short-lasting effect, though this could not be ascertained clearly. There were no visible effects after a second injection. The thyroid stimulating hormone (TSH) response curve after TRH administration in the depressive patients group was blunted in comparison with that in a matched control group of normals.
